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A B S T R A C T
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe pulmonary infection, with ∼35 %
mortality. Spike glycoprotein (S) of MERS-CoV is a key target for vaccines and therapeutics because S mediates
viral entry and membrane-fusion to host cells. Here, four different S subunit proteins, receptor-binding domain
(RBD; 358–606 aa), S1 (1–751 aa), S2 (752–1296 aa), and SΔTM (1–1296 aa), were generated using the ba-
culoviral system and immunized in mice to develop neutralizing antibodies. We developed 77 hybridomas and
selected five neutralizing mAbs by immunization with SΔTM against MERS-CoV EMC/2012 strain S-pseudotyped
lentivirus. However, all five monoclonal antibodies (mAb) did not neutralize the pseudotyped V534A mutation.
Additionally, one mAb RBD-14F8 did not show neutralizing activity against pseudoviruses with amino acid
substitution of L506 F or D509 G (England1 strain, EMC/2012 L506 F, and EMC/2012 D509 G), and RBD-43E4
mAb could not neutralize the pseudotyped I529 T mutation, while three other neutralizing mAbs showed broad
neutralizing activity. This implies that the mutation in residue 506–509, 529, and 534 of S is critical to generate
neutralization escape variants of MERS-CoV. Interestingly, all five neutralizing mAbs have binding affinity to
RBD, although most mAbs generated by RBD did not have neutralizing activity. Additionally, chimeric anti-
bodies of RBD-14F8 and RBD-43E4 with human Fc and light chain showed neutralizing effect against wild type
MERS-CoV KOR/KNIH/002, similar to the original mouse mAbs. Thus, our mAbs can be utilized for the iden-
tification of specific mutations of MERS-CoV.
1. Introduction
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes
an acute and severe respiratory disease with high mortality in humans
(van Boheemen et al., 2012). MERS-CoV was first identified in the
Kingdom of Saudi Arabia in 2012, which is a single and positive
stranded RNA virus (de Groot et al., 2013). As of 8th July 2019, 2,428
laboratory-confirmed cases of MERS worldwide, including 838 asso-
ciated deaths, with a mortality rate of 34.5 %, were reported. Dro-
medary camels are widely considered as the source of the transmission
of MERS-CoV (Hemida et al., 2017). The rate of human transmission
among household contacts of MERS patients has been approximately 5
% based on serological analysis (Drosten et al., 2014). However, no-
socomial super-spreading events occurred in South Korea in 2015 and
the rapid and widespread of MERS-CoV from May to July 2015 raised
strong concerns regarding the possible generation of mutations with
enhanced sequential human infection (Cho et al., 2016).
The spike (S) glycoprotein of MERS-CoV is a critical viral factor for
human receptor-mediated infection and is cleaved into a receptor-
binding subunit S1 and a membrane-fusion subunit S2 during the in-
fection process (Wang et al., 2013, 2014; Yu et al., 2015). Since the
MERS outbreak in South Korea, 13 new viral genomes from 14 infected
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Korean patients were isolated, and 12 of these genomes were identified
to possess a point mutation in the receptor-binding domain (RBD) of the
S glycoprotein (Kim et al., 2016a, b; Min et al., 2016). Specifically, 11
of these genomes showed an I529 T mutation in RBD, and 1 showed a
D510 G mutation, which exhibits reduced affinity of RBD to its cellular
receptor, human dipeptidyl peptidase 4 (DPP4; also known as CD26),
compared with the wild type RBD, suggesting that MERS-CoV adapta-
tion during human-to-human spread may be driven to escape from
neutralizing antibodies, rather than to evolve for a stronger affinity to
DPP4 (Kim et al., 2016b; Park et al., 2016). Therefore, several mAbs
against different epitopes within S might be used as a prophylactic or
therapeutic agent to avoid the immune escape of the virus.
Because the conformation of RBD in full-length S and its truncated
versions may differ, recombinant RBD subunit protein itself may not
induce neutralizing antibodies as efficiently as a larger subunit such as
S1 or transmembrane deleted S (SΔTM) (Wang et al., 2015). In this
study, we produced recombinant RBD, S1, S2, and SΔTM proteins from
insect cells using baculovirus and induced neutralizing antibodies from
the mice by immunization with each subunit protein. We developed
mAbs by hybridoma technique and several mAbs were selected and
characterized for their neutralizing activity against 15 different MERS-
CoV S-pseudotyped virus and wild type KOR/KNIH/002. The results of
this study are expected to contribute to the development of diagnostic
tools of MERS-CoV S mutation as well as for mAb-based therapeutics.
2. Materials and methods
2.1. Cells
HEK 293 T/17 and 786-O cells (ATCC, Manassas, VA, USA) were
grown at 37 °C and 5 % CO2 in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Waltham, MA, USA) supplemented with 10 % fetal
bovine serum (FBS; Gibco, Waltham, MA, USA) and 1 % penicillin/
streptomycin (Invitrogen). Spodoptera frugiperda(Sf9) cells (Thermo
Fisher, Waltham, MA, USA) were cultured in Sf-900™ II SFM medium
(Gibco) and 1 % penicillin/streptomycin (WELGENE, Daegu, South
Korea) at 27 °C, non-humidified, non-CO2 incubator with 120 rpm
suspension.
2.2. Construction of recombinant mammalian expression vectors containing
MERS-CoV EMC/2012 SΔER sequence
Human codon-optimized gene encoding SΔER (1–1338 aa) of MERS-
CoV EMC/2012 isolate (GenBank accession number: JX869059),
mammalian codon-optimized SΔER of KOR/KNIH/002 strain (GenBank
accession number: KT029139) and England1 strain (GenBank accession
number: KC164505) synthesized by Genscript (NJ, USA) were cloned
into the pCMV/R 8κB (Rao et al., 2008) using SalI and BamHI sites.
Other mutated genes encoding substituted residues in RBD of S were
generated by site-directed mutagenesis (QuikChange II XL Site-Directed
Mutagenesis. Kit; Agilent Technologies, Santa Clara, CA, USA) using the
EMC/2012 strain S gene as a template. The sequences of strains with
mutations in MERS-CoV RBD residues were obtained from the GenBank
database (Tables 1 and 2). All insert genes in the recombinant plasmids
were verified by sequencing (Cosmogenetech, Seoul, Korea).
2.3. Generation of recombinant baculovirus containing MERS-CoV spike
subunit protein genes
Insect cell codon-optimized gene for S of EMC/2012 strain was
synthesized by Bioneer (Daejeon, Korea) and used as a PCR template.
Four MERS-CoV spike subunit genes, SΔTM (1–1296 aa), S1 (1–751 aa),
S2 (752–1296 aa), and RBD (358–606 aa), were PCR-amplified with
primers containing BamHI site in the forward primer and 6× His-tag
sequence and SalI site in the reverse primer. For S2 and RBD, the gp67
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following the BamHI site. Each PCR product was cloned into the
pFastBac donor vector (Bac-to-Bac™ Baculovirus Expression System,
Thermo Fisher) using BamHI and SalI restriction sites. Infectious re-
combinant baculovirus was prepared as described previously (Yang
et al., 2015a).
2.4. Production and purification of recombinant S subunit proteins from
insect cells
For recombinant protein expression, Sf9 insect cells (2× 106 cells/
ml, 200ml) were infected with the supernatants containing re-
combinant baculovirus and cultured for three days (27 °C, 120 rpm),
and then the culture media were collected and concentrated by the
ammonium sulfate precipitation method (7M ammonium sulfate). The
precipitate was re-dissolved in a buffer solution [20mM Tris-HCl (pH
8.0), 0.5M NaCl, 5 mM imidazole], and then histidine-tagged proteins
were purified using a metal affinity column with immobilized nickel as
a ligand (ADAR Biotech, Rehovot, Israel). The purified protein was
eluted from the column with elution buffer [20mM Tris-HCl (pH 8.0),
0.5 M NaCl, 250mM imidazole], subjected to dialysis in 20mM Tris-
HCl buffer at pH 8.0 containing 10 % glycerol, and then concentrated to
0.25mg/ml.
2.5. Immunization and hybridoma generation
Female Balb/c mice were purchased from Nara Biotech, Korea. The
animal experiments for immunization and collecting ascites were ap-
proved by the IACUC (IACUC protocol number ATGen 2016-0113-06
and ATGen 2016-0113-07, respectively). Mice were immunized twice
with a 2-week interval with 25 μgMERS-CoV recombinant S subunit
protein (SΔTM, S1, S2, and RBD) combined with 150 μL Freund’s
complete adjuvant (Sigma, St Louis, CA, USA) via the subcutaneous
Table 2
Amino acid sequence variation within the receptor-binding domain of MERS-CoV Spike.
Virus isolate GenBank Accession No. (Protein ID) Spike RBD
424 431 434 460 482 506 509 510 522 529 530 534 582










4 Riyadh2 AGV08584.1 A
5 Al-Hasa8c AGV08438.1 I
6 Riyadh9 AHI48528.1 P V




9 Jeddah_C9313 AID55087.1 　 　 　 　 　 　 　 　 H 　 　 　 　
10 KOR/CNUH_SNU/122 ALK80291.1 G
11 KOR/CNUH_SNU/016_06 ALK80192.1 T
12 KOR/KNIH/002 AKL59401.1 L
Fig. 1. Production of SΔTM, S1, S2, and RBD subunit recombinant proteins by baculovirus system. A. Schematic diagram for the domain structure of MERS-CoV Spike
(S) protein. B. SDS-PAGE and Coomassie blue staining of purified recombinant S subunit proteins from the insect cell culture supernatant: SΔTM (1–1296 aa), S1
(1–751 aa), S2 (752–1296 aa), and RBD (358–606 aa).
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route. The mice were sacrificed 3 or 4 days after the last immunization,
and their splenocytes were fused with mouse myeloma cells FO at a 5:1
ratio in the presence of PEG1500 (Roche, Basel, Switzerland). After 10
days of culture with hypoxanthine-aminopterin-thymidine medium,
ELISA-positive hybridomas were subjected to limited dilutions and
further selected based on pseudovirus neutralization results. For large-
scale mAb production, ascites fluid from mice inoculated with the hy-
bridomas was collected and purified using a rProtein A Agarose Resin
(Amicogen, Jinju, Korea). Isotype classification of the purified mAbs
was performed using the Pierce Rapid ELISA Mouse mAb Isotyping Kit
(Thermo) according to the manufacturer’s instructions.
2.6. Production of chimeric monoclonal antibodies h14F8 and h43E4
The chimeric mAbs for RBD-14F8 and RBD-43E4 were produced as
described previously (Dang et al., 2013). Briefly, RNA was extracted from
hybridoma cells and the first-strand cDNA was produced. The VH and VL
regions were amplified using primers restricted with SfiI and NheI or BglII
and cloned into the expression vector to produce chimeric IgG. The se-









tccagcttggtgcctcca-3′. Chimeric antibody for RBD-14F8 was named
h14F8 possessing human IgG1 Fc and human lambda1 light chain. Chi-
meric antibody for RBD-43E4 was named h43E4 with human IgG1 Fc
and human kappa 1 light chain. Each prepared DNA plasmid was tran-
siently transfected into HEK 293-FT cells (Invitrogen) using poly-
ethyleneimine, and cell culture supernatant (Freestyle 293 Expression
media, Thermo Fisher Scientific) was harvested after 7 days. Antibody
was purified using Poly-Prep chromatography column (Bio-Rad, Her-
cules, CA, USA) packed with Protein A. Purified h14F8 (5.37mg) and
h43E4 (2.9mg) were obtained.
Fig. 2. Pseudovirus neutralizing activity of hybridomas generated using splenocytes of mice that were immunized with SΔTM, S1, S2, and RBD recombinant protein.
A. Distribution of neutralizing activity of 77 hybridomas against MERS-CoV EMC/2012 Spike (S)-pseudotyped lentivirus. Hybridoma culture supernatant was
incubated with MERS-CoV EMC/2012 pseudovirions for 60min at 37 °C and added to 786O cells, incubated for 6 h, replaced with fresh medium, and then analyzed
for luciferase-reporter activity 3 days later. The relative luminescence unit (RLU) was converted to % neutralizing activity. B. Neutralizing activity of the selected
hybridomas against EMC/2012 (left) and KOR/KNIH/002 (right) strain of pseudovirions. Among 77 hybridomas, selected 15 hybridomas (1 by S1, 11 by SΔTM, and
2 by S2) were tested for their neutralizing activity against indicated pseudovirions. Four ten-fold serial dilutions from 1/5 of hybridoma culture supernatant were
used for EMC/2012 pseudovirions, and undiluted culture supernatant was used for KOR/KNIH/002 pseudovirions. C. Binding domain of selected mAbs within S
protein. Seven mAbs were purified, and each binding region was assessed using ELISA. The value indicates the OD after coating the 96-well plate with each S subunit
antigen.
Table 3
Characterization of mAbs developed by MERS-CoV S subunit proteins.





6E6 IgG1 κ S1-non RBD SΔTM
14F8 IgG1 κ RBD
23D3 IgG1 λ RBD
25E4 IgG1 κ RBD
40G7 IgG1 κ RBD
43E4 IgG2b κ RBD
14H8 IgG2b κ S2 S2
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2.7. Pseudovirus production
Lentivirus based MERS-CoV S-pseudotyped particles were gener-
ated. HEK 293 T/17 cells (4× 106) were seeded in DMEM without
antibiotics into 100-mm Petri dishes at a ratio that will yield 70–90 %
confluence at the time of transfection. Lentiviral pseudovirions ex-
pressing MERS-CoV S protein were produced by co-transfection of HEK
293 T cells with three plasmids: 7 μg of pHR’CMV-Luc, 7 μg of pCMV
ΔR8.2 (Naldini et al., 1996), and 100 ng of pCMV/R 8κB-S encoding
plasmids using Lipofectamine 2000 (Invitrogen). The medium was
replaced after overnight incubation. Supernatants containing the viral
pseudotyped particles were harvested 48–72 h after transfection, fil-
tered using a 0.45-μm filter syringe and stored at −80 °C as aliquots
(Kim et al., 2007). Titration of pseudovirus was performed using Len-
tivirus-Associated p24 ELISA Kit (Cell Biolabs, San Diego, CA, USA).
2.8. Pseudovirus neutralization assay
The 786-O cells were plated at a density of 1×104 cells/well in 96-
well plate with complete DMEM (10 % FBS, 1 % penicillin/
Fig. 3. Dose-dependent neutralizing activity of purified mAbs against 11 different MERS-CoV Spike (S)-pseudotyped virions. Each mAb was diluted 2-fold from 50 ng
and tested. mAb was incubated with indicated MERS-CoV S-pseudotyped virions for 60min at 37 °C and added to 786O cells, incubated for 6 h, replaced with fresh
medium, and analyzed for luciferase-reporter activity 3 days later. The RLU value was converted to % neutralizing activity. The data is represented as the
mean ± standard deviation from at least two independent experiments. Statistical significance was determined by one-way ANOVA followed by Tukey’s test.
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streptomycin) at 37 °C in a humidified atmosphere of 5 % CO2 the day
before pseudo-viral infection until 95 % confluence was achieved. After
incubation of 50 μL of 2×106 MERS-CoV S-pseudotyped particles and
20 μL of serially diluted mouse immune serum or neutralizing antibody
as positive control (Sino Biological Inc., Beijing, China) for 1 h at room
temperature, the mixtures were added to the cells and wells were re-
placed with 100 μL of fresh media after 6 h of incubation. Cells were
lysed after 72 h with 20 μL of lysis buffer (Promega, Promega, Madison,
WI, USA) and transferred to Opaque plate (Perkin-Elmer, Waltham, MA,
USA) (Kim et al., 2007). Luciferase activity was measured by adding
40 μL of the substrate (Promega) using SpectraMax L Microplate Reader
(Molecular Devices, San Jose, CA, USA).
2.9. Plaque reduction neutralization test (PRNT) of wild type MERS-CoV
MERS-CoV (0.004m.o.i. (multiplicity of infection) in 24 well) KOR/
KNIH/002, provided by the Korea Centers for Disease Control and
Prevention (Yang et al., 2015b), was pre-incubated with each mAb and
then added to Vero cells. After 1 h of incubation, cells were overlaid
with a medium containing 1 % Sea-plaque agarose (Lonza, Basel,
Switzerland). At 48 h after MERS-CoV infection, cells were fixed and
Fig. 4. Dose-response curve of neutralizing
activity of mAbs against three pseudoviruses
with MERS-CoV RBD identified in 2015 during
the Korean MERS outbreak (D510 G, I529 T,
and V530 L respectively). Each mAb was di-
luted 2-fold from 50 ng and tested. mAb was
incubated with indicated MERS-CoV S-pseu-
dotyped virions for 60min at 37 °C and added
to 786O cells, incubated for 6 h, replaced with
fresh medium, and analyzed for luciferase-re-
porter activity 3 days later. The RLU value was
converted to % neutralizing activity. The data
is represented as the mean ± standard devia-
tion from at least two independent experi-
ments. Statistical significance was determined
by one-way ANOVA followed by Tukey’s test.
Table 4
Humanized mAb characteristics.
Humanized mAb Isotype Light chain
Hu-14F8 hIgG1 hLambda1
Hu-43E4 hIgG1 hKappa1
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stained with anti-MERS-CoV N protein antibody (Sino Biological Inc.)
to count the viral plaques.
2.10. Enzyme-linked immunosorbent assay (ELISA)
RBD-, S1-, S2-, and SΔTM-specific antibody in the hybridoma cul-
ture supernatant was measured by ELISA as described previously (Kim
et al., 2015; Shere et al., 1997).
2.11. Statistical analysis
Analyses were performed using Prism 5 (GraphPad, San Diego, CA)
or Excel program (Microsoft office). Differences between groups were
analyzed by one-way analysis of variance (ANOVA) followed by
Tukey’s test. P values of< 0.05 were considered statistically sig-
nificant.
3. Results
3.1. MERS-CoV S-specific antibody generation from mice immunized with
recombinant S subunit proteins
To develop neutralizing mAbs with different epitopes, several S
subunit proteins were designed as antigen. The MERS-CoV S glyco-
protein consists of a globular S1 domain at the N-terminal region
containing the RBD that is responsible for binding to the host cellular
receptor DPP4, followed by membrane-proximal S2 domain and a
transmembrane domain (Du et al., 2013) (Fig. 1A). Recombinant pro-
teins of SΔTM (1–1296 aa), S1 (1–751 aa), S2 (752–1296 aa), and RBD
(358–606 aa) corresponding to the amino acid sequence of MERS-CoV
EMC/2012 strain were produced from the Sf9 insect cells using bacu-
lovirus expression system (Fig. 1B). These proteins were immunized
into Balb/c mice, and the hybridoma fusion was performed using spleen
cells. Then, the culture supernatant of hybridoma cells was subjected to
ELISA to assess whether they secrete the antibody that can bind to S
subunit proteins (data not shown). A total of 77 hybridomas secreted
antibodies binding to S subunit proteins; 25 from SΔTM, 29 from S1, 11
from RBD, and 12 mAbs from S2.
3.2. Identification of neutralizing mAbs against MERS-CoV S using
pseudovirus system
MERS-CoV S-pseudotyped lentivirus was produced to evaluate the
neutralizing activity of antibodies secreted by hybridoma cells.
Pseudovirus expressing the MERS-CoV spike protein was generated by
co-transfection of the plasmids of HIV-1 Gag/pol, luciferase-expressing
HIV-1, and S into HEK 293 T cells. We used S genes without an en-
doplasmic reticulum signal (SΔER) (Kim et al., 2016b). SΔER gene of
EMC/2012, England 1, and KOR/KNIH/002 strains were cloned
(Table 1) and the other 13 RBD genes of naturally occurring strains of
MERS-CoV were cloned based on the EMC/2012 strain S gene, except
for the RBD region (Table 2).
Next, the neutralizing activity of a panel of ELISA-positive 77 hy-
bridomas was evaluated against MERS-CoV EMC/2012 strain S-pseu-
dotyped virions. The inhibition of the pseudovirus infection by anti-
bodies was quantified by luciferase activity in pseudovirus-infected
cells (Fig. 2A). Selected clones were further tested against S-pseudo-
typed KOR/KNIH/002 strain (Fig. 2B), and seven clones were selected:
six clones (6, 23, 25, 40, 43, and 14) and one clone (14S2) generated by
SΔTM and S2 immunization, respectively. Among these clones, 6
(SΔTM) did not neutralize both EMC/2012 and KOR/KNIH-002 strains,
and 14 (S2) inhibited the entry of both pseudotyped strains to the target
786O cells with approximately 50 % activity. All these seven clones
were further sub-cloned and finally, mAbs S1-6E6, RBD-14F8, RBD-
23D3, RBD-25E4, RBD-40G7, RBD-43E4 by SΔTM, and S2-14H8 by S2
were purified and characterized for IgG subclass and light chain type
(Table 3). Upon examination of the binding domain of the SΔTM-gen-
erated mAbs, S1-6E6 bound to non-RBD S1 and the other neutralizing
Fig. 5. Epitope-specific neutralizing activity of chimeric h14F8 and h43E4 against MERS-CoV Spike (S)-pseudotyped virions. A. Fc/light chain-humanized chimeric
h14F8 (left) and h43E4 (right) mAb purified from 293 F cell culture supernatant after transfection with relevant DNA plasmids and run on the 4∼20 % SDS-PAGE
followed by Coomassie-blue staining. Re, reducing condition; NR, non-reducing condition. B. h14F8 (left) and h43E4 (right) mAb was diluted 4-fold from 12.5 ng and
were neutralized against EMC/2012, KOR/KNIH/002, L506 F, D509 G, D510 G, I529 T, and V530 L pseudotyped virions. The luciferase activity of pseudovirus was
converted to % neutralizing activity. C. Neutralizing activity of both mouse and chimeric 14F8 and 43E4 against wild type MERS-CoV KOR/KNIH/002 strain was
assessed by PRNT. mAbs were diluted 4-fold from 100 ng and were tested. The data is representative of at least two independent experiments.
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mAbs showed affinity to RBD (Fig. 2C). Taken together, several neu-
tralizing mAbs were generated by SΔTM immunization, although the
antibodies developed by RBD immunization did not induce a neu-
tralization effect under our experimental condition (Fig. 2A).
3.3. Neutralizing effect of mAbs against various MERS-CoV S pseudoviruses
To evaluate whether the mAbs have cross-protective capability
against various MERS-CoV strains, we further examined neutralizing
activity against our MERS-CoV S pseudovirus, in which the S gene
contained different RBD region of England1/ England-Qatar (L506 F),
Qatar3 (S460 F), Riyadh1/Bisha1 (D509 G), Riyadh2 (V534A), Al-
Hasa8c (N582I), Riyadh9 (A431 P and A482 V), Asir2f (A434 V),
Riyadh345/Riyadh59 (T424I), Jeddah_C9313 (Q522 H), KOR/
CNUH_SNU/122 (D510 G), KOR/CNUH_SNU/016_06 (V529 T), or
KOR/KNIH/002 (V530 L) strains (Table 2). Of these, the EMC/2012-
V534A (Riyadh2) variant exhibited neutralization resistance to our
mAbs (data not shown).
Among five mAbs that could bind to RBD, three mAbs (RBD-23D3,
RBD-25E4, and RBD-40G7) showed broad neutralizing activity against
14 different S-pseudotyped viruses (Figs. 3 and 4). However, RBD-14F8
mAb did not neutralize three pseudoviruses possessing amino acid
substitution of L506 F or D509 G (SΔER of England1 and RBD gene of
England1/ England-Qatar and Riyadh1/Bisha1 strain based on EMC/
2012 SΔER gene), implying that 506–509 residue mutation of EMC/
2012 S can elicit neutralization escape from RBD-14F8 (Fig. 3). RBD-
43E4 mAb did not neutralize KOR/CNUH_SNU/016_06 RBD (I529 T)
pseudotype (Fig. 4). As expected, S1-6E6 that bound to the non-RBD
region of S1 did not show any neutralizing activity even at the highest
antibody dose of 20 ng. S2-14H8 mAb, which showed binding affinity
to S2, showed partial neutralizing effect compared with other RBD-
binding neutralizing mAbs (Figs. 3 and 4).
3.4. Neutralizing effect of humanized RBD-14F8 and RBD-43E4 against
pseudovirus and wild type MERS-CoV
To make mAbs available for human clinical use or standard of
human sample analysis, RBD-14F8 and RBD-43E4 were genetically
engineered to increase their similarity to antibody variants produced
naturally in humans; their Fc region was replaced by human IgG1 Fc,
and the light chain was replaced with human lambda1 and kappa1
chain (Table 4). The humanized antibody for 14F8 and 43E4 was
produced using 293 F cells by transfection of cloned antibody DNA
plasmids and purified with Protein A column (Fig. 5A). These chimeric
mAbs neutralized the pseudoviruses with S of EMC/2012, KOR/KNIH/
002, and V530 L variant of EMC/2012. However, h14F8 showed lower
neutralization activity against pseudotyped D509 G, D510 G, and
especially L506 F variant, and h43E4 did not neutralize the pseudo-
typed I529 T variant at all (Fig. 5B), which were also observed in mouse
mAb RBD-14F8 and RBD-43E4, respectively.
Neutralizing activity of both mouse and chimeric mAbs of RBD-
14F8 and RBD-43E4 were verified by PRNT assay against wild type
MERS-CoV KOR/KNIH/002 strain (Fig. 5C). As controls, S2-6E6 and
RBD-23D3 were included in PRNT. S1-6E6 did not neutralize, but RBD-
23D3 neutralized the wild type strain in a dose-dependent manner, as in
previous pseudovirus neutralization. Collectively, chimeric RBD-14F8
and RBD-43E4 mAb showed similar neutralization effect as the original
mouse mAb RBD-14F8 and RBD-43E4, respectively, suggesting that
these chimeric mAbs can be used to distinguish mutations in specific
residue 509 or 529 of MERS-CoV clinical isolates.
4. Discussion
In this study, we aimed to develop mAbs specific to MERS-CoV to
utilize them as therapeutics or diagnostic tools of variant MERS-CoV
strains. MERS-CoV is a single, positive stranded RNA virus of
approximately 30 kb, which encodes four major viral structural pro-
teins, including S, envelope, membrane, and nucleocapsid as well as
several accessory proteins. Since MERS-CoV S mediates viral attach-
ment and fusion to human cells via human cellular receptor DPP4, also
known as CD26, we considered S as a target for mAb development in-
cluding neutralizing antibodies.
We generated mAbs by mouse hybridoma technique using re-
combinant S subunit proteins as antigens. We selected the 7 mAbs from
77 hybridomas based on the specific binding ability to each S subunit
and characterized their neutralizing activity against diverse MERS-CoV
S pseudoviruses: six mAbs were developed by SΔTM showing specific
binding affinity to non-RBD S1, and RBD; the other one mAb was
produced by S2 subunit protein immunization. Polyclonal serum de-
veloped by S1 showed high neutralizing activity against both EMC/
2012 and KOR/KNIH/002 S pseudovirions, which was comparable to
SΔTM immunization (data not shown). However, we failed to obtain
potent neutralizing mAbs from S1-immunized mice under our experi-
mental condition. Our RBD-specific mAbs, RBD-14F8, -23D3, -25E4,
-40G7, and -43E4, showed higher neutralizing potency than other non-
RBD-binding mAbs (S1-6E6 for non-RBD S1, and S2-14H8 for S2),
which is consistent with the fact that most reported neutralizing mAbs
are RBD-specific (Pascal et al., 2015; Wang et al., 2018; Ying et al.,
2014). The mAbs developed by other groups, CDC-C2, m336, and
REGN3051, also bind to RBD and potently neutralize MERS-CoV (de
Wit et al., 2018; Pascal et al., 2015; Wang et al., 2018; Ying et al.,
2014). Meanwhile, it has also been reported that non-RBD S1-specific
mAbs, G2 and 5F9, and S2-specific mAb G4 neutralized MERS-CoV
(Chen et al., 2017; Pallesen et al., 2017; Wang et al., 2015; Zhang et al.,
2018).
In our study, the RBD subunit protein itself could not induce suffi-
cient neutralizing activity, unlike SΔTM protein, which suggests that
the design of antigen to possess an appropriate structural conformation
is crucial for developing vaccines and therapeutic neutralizing anti-
bodies. The baculoviral expression system produced all recombinant S
subunit proteins in this study. Hence, the baculovirus-expressed SΔTM
can be considered as a promising MERS-CoV vaccine antigen given its
ability to induce potent neutralizing antibodies, although it does not
have trimerization tag for pre-fusion conformation (Pallesen et al.,
2017) and may have different glycosylation patterns as compared to
mammalian-expressed S proteins (Li et al., 2016).
Our mAbs RBD-23D3, RBD-25E4, and RBD-40G7 targeting RBD
showed high cross-neutralizing activities against 14 different MERS-
CoV S pseudoviruses. In contrast, the transduction of pseudovirions
with the change of V534A in RBD of EMC/2012 was not inhibited by
any of our mAbs. Interestingly, two mAbs, RBD-14F8 and RBD-43E4,
did not neutralize another pseudovirion with specific mutation in RBD
region: RBD-14F8 could not neutralize the pseudovirions with changes
in the amino acid residue at 506, 510, and particularly at 509 site
(D509 G); meanwhile, RBD-43E4 did not neutralize pseudovirions with
the mutation at 529 amino acid residue (I529 T) compared with the
EMC/2012 strain S sequence. A single amino acid change in the RBD
region was identified in 2015 Korea outbreak patients and it was re-
ported that the mutation of either D510 G or I529 T reduces the viral
affinity to human cellular receptor DPP4 (Kim et al., 2016b). In our
experiments, lower luciferase activity was also observed in 786O target
cells after pseudovirus infection with D510 G or I529 T mutation. The
mAb CDC-C2 developed by US NIH possessed binding affinity to RBD
and lost neutralizing effect against pseudovirions with mutations at
509, 512, 534, 536, 539, 540, or 542 amino acid residues from EMC/
2012 strain S amino acid sequence (Wang et al., 2018). The common
amino acid that influences the loss of neutralization between CDC-C2
and our RBD-14F8 mAbs is the 509 residue. S2-binding S2-14H8
showed partial neutralizing activity against all tested pseudoviruses,
and non-RBD S1-binding S1-6E6 did not hinder cell entry of the entire
tested pseudoviruses at all. More structural data are needed to de-
termine precise epitopes for each neutralizing mAb and the mechanisms
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by which combining the mAbs might delay viral escape.
Wild type MERS-CoV KOR/KNIH/002 strain also showed suscept-
ibility to RBD-23D3, -14F8, and -43E4 mAbs, regardless of its origin
(either mouse or Fc-/light chain-humanized chimeric antibody).
Humanized mAb may be utilized as caliber to measure human immune
responses or therapeutic purposes in humans. However, symptoms
often appear after the peak of viremia; combined neutralizing mAbs
therapy would have to be used before the onset of symptoms to be early
enough to avoid viremia. In addition, mAbs targeting non-RBD epitopes
of MERS-CoV S may have potential clinical applications in the pre-
vention and/or treatment of disease. With animal models that reflect
human MERS-CoV infection, the protective effect of these mAbs may be
better assessed.
In conclusion, several mAbs developed by murine hybridoma tech-
nique may be utilized as MERS-CoV diagnostics distinguishing S 509
and 529 escape mutant strains or combined therapeutic antibodies with
humanized forms.
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